An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia

Ryo Ito, Noriko Satoh-Asahara, Hajime Yamakage, Yousuke Sasaki, Shinji Odori, Shigeo Kono, Hiromichi Wada, Takayoshi Suganami, Yoshihiro Ogawa, Koji Hasegawa, Akira Shimatsu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aim: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid(EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid(DHA) and dihomo-γ-linolenic acid (DGLA), relative to arachidonic acid(AA), in obese Japanese patients with dyslipidemia. Methods: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obese patients with(n=94) and without (n=31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment(1.8g daily, n=45) or treatment without EPA(control, n=43). Results: At baseline, the ratios of DHA/AA and DGLA/AA were significantly(P<0.05) higher in obese patients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index(CAVI) (an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio(P<0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. Conclusion: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obese patients with dyslipidemia.

Original languageEnglish
Pages (from-to)248-260
Number of pages13
JournalJournal of atherosclerosis and thrombosis
Volume21
Issue number3
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Vascular Stiffness
Eicosapentaenoic Acid
Dyslipidemias
Arachidonic Acid
Stiffness
Docosahexaenoic Acids
Ankle
Blood Vessels
alpha-Linolenic Acid
Adiponectin
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Regression analysis
Epidemiologic Studies
Hemoglobins
Triglycerides
Cardiovascular Diseases

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia. / Ito, Ryo; Satoh-Asahara, Noriko; Yamakage, Hajime; Sasaki, Yousuke; Odori, Shinji; Kono, Shigeo; Wada, Hiromichi; Suganami, Takayoshi; Ogawa, Yoshihiro; Hasegawa, Koji; Shimatsu, Akira.

In: Journal of atherosclerosis and thrombosis, Vol. 21, No. 3, 01.01.2014, p. 248-260.

Research output: Contribution to journalArticle

Ito, R, Satoh-Asahara, N, Yamakage, H, Sasaki, Y, Odori, S, Kono, S, Wada, H, Suganami, T, Ogawa, Y, Hasegawa, K & Shimatsu, A 2014, 'An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia', Journal of atherosclerosis and thrombosis, vol. 21, no. 3, pp. 248-260. https://doi.org/10.5551/jat.19976
Ito, Ryo ; Satoh-Asahara, Noriko ; Yamakage, Hajime ; Sasaki, Yousuke ; Odori, Shinji ; Kono, Shigeo ; Wada, Hiromichi ; Suganami, Takayoshi ; Ogawa, Yoshihiro ; Hasegawa, Koji ; Shimatsu, Akira. / An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia. In: Journal of atherosclerosis and thrombosis. 2014 ; Vol. 21, No. 3. pp. 248-260.
@article{eda037903c004e6aaf1a3f41c4ebc706,
title = "An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia",
abstract = "Aim: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid(EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid(DHA) and dihomo-γ-linolenic acid (DGLA), relative to arachidonic acid(AA), in obese Japanese patients with dyslipidemia. Methods: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obese patients with(n=94) and without (n=31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment(1.8g daily, n=45) or treatment without EPA(control, n=43). Results: At baseline, the ratios of DHA/AA and DGLA/AA were significantly(P<0.05) higher in obese patients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index(CAVI) (an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio(P<0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. Conclusion: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obese patients with dyslipidemia.",
author = "Ryo Ito and Noriko Satoh-Asahara and Hajime Yamakage and Yousuke Sasaki and Shinji Odori and Shigeo Kono and Hiromichi Wada and Takayoshi Suganami and Yoshihiro Ogawa and Koji Hasegawa and Akira Shimatsu",
year = "2014",
month = "1",
day = "1",
doi = "10.5551/jat.19976",
language = "English",
volume = "21",
pages = "248--260",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "3",

}

TY - JOUR

T1 - An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia

AU - Ito, Ryo

AU - Satoh-Asahara, Noriko

AU - Yamakage, Hajime

AU - Sasaki, Yousuke

AU - Odori, Shinji

AU - Kono, Shigeo

AU - Wada, Hiromichi

AU - Suganami, Takayoshi

AU - Ogawa, Yoshihiro

AU - Hasegawa, Koji

AU - Shimatsu, Akira

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aim: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid(EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid(DHA) and dihomo-γ-linolenic acid (DGLA), relative to arachidonic acid(AA), in obese Japanese patients with dyslipidemia. Methods: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obese patients with(n=94) and without (n=31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment(1.8g daily, n=45) or treatment without EPA(control, n=43). Results: At baseline, the ratios of DHA/AA and DGLA/AA were significantly(P<0.05) higher in obese patients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index(CAVI) (an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio(P<0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. Conclusion: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obese patients with dyslipidemia.

AB - Aim: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid(EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid(DHA) and dihomo-γ-linolenic acid (DGLA), relative to arachidonic acid(AA), in obese Japanese patients with dyslipidemia. Methods: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obese patients with(n=94) and without (n=31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment(1.8g daily, n=45) or treatment without EPA(control, n=43). Results: At baseline, the ratios of DHA/AA and DGLA/AA were significantly(P<0.05) higher in obese patients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index(CAVI) (an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio(P<0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. Conclusion: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obese patients with dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=84897059442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897059442&partnerID=8YFLogxK

U2 - 10.5551/jat.19976

DO - 10.5551/jat.19976

M3 - Article

VL - 21

SP - 248

EP - 260

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 3

ER -